Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
NASDAQ:TGTX
TGTX Stock Chart & Stats
$27.96
$0.31(1.11%)
At close: 4:00 PM EST
$27.96
$0.31(1.11%)
Day’s Range― - ―
52-Week Range$25.28 - $46.48
Previous CloseN/A
Volume723.16K
Average Volume (3M)1.60M
Market Cap
$4.46B
Enterprise Value$4.78B
Total Cash (Recent Filing)$141.97M
Total Debt (Recent Filing)$260.73M
Price to Earnings (P/E)9.6
Beta0.69
Next Earnings
May 11, 2026EPS Estimate
0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding159,688,260
10 Day Avg. Volume1,637,963
30 Day Avg. Volume1,598,534
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)6.64
Price to Sales (P/S)6.98
P/FCF Ratio-172.18
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue7.75
Enterprise Value/Gross Profit9.27
Enterprise Value/Ebitda35.54
Forecast
1Y Price Target
$42.00Price Target Upside50.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)1.59
Revenue Forecast (FY)$897.58M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPlanned pivotal trials for an intravenous dosing option and a self-administered subcutaneous formulation could expand the label and attract new patient segments if results are favorable.
Commercial AdoptionRising new patient starts, durable treatment persistence, and expanding adoption among high-prescribing clinicians support continued market share gains for Briumvi.
Regulatory ApprovalsApproval across multiple international markets broadens the addressable patient base and may generate incremental royalty and reimbursement opportunities for Briumvi.
Bears Say
Best-in-class ThreatA future BTK drug with comparable efficacy but a cleaner safety profile and no routine monitoring requirement could be perceived as best-in-class and materially reduce demand for current CD20 injectables.
Competitive Portfolio ExpansionRival plans to expand subcutaneous and oral treatment options increase therapeutic choices and may intensify pricing and market-share pressure for Briumvi in core markets.
Oral BTK CompetitionAn oral BTK inhibitor demonstrating similar reductions in relapses and MRI activity could prompt patients and clinicians to switch away from injectable CD20 therapies like Briumvi.
TG Therapeutics News
TGTX FAQ
What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest stock price was $25.28 and its highest was $46.48 in the past 12 months.
What is TG Therapeutics’s market cap?
TG Therapeutics’s market cap is $4.46B.
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s upcoming earnings report date is May 11, 2026 which is in 55 days.
How were TG Therapeutics’s earnings last quarter?
TG Therapeutics released its earnings results on Feb 26, 2026. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.352 by -$0.212.
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate is 0.28.
How many shares outstanding does TG Therapeutics have?
TG Therapeutics has 159,688,260 shares outstanding.
What happened to TG Therapeutics’s price movement after its last earnings report?
TG Therapeutics reported an EPS of $0.14 in its last earnings report, missing expectations of $0.352. Following the earnings report the stock price went up 4.181%.
Which hedge fund is a major shareholder of TG Therapeutics?
Currently, no hedge funds are holding shares in TGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TG Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.00 (50.21% Upside)
$42.00 (50.21% Upside)
Blogger Sentiment
Bullish
TGTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 49.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.55%
12-Months-Change
Fundamentals
Return on Equity
101.12%
Trailing 12-Months
Asset Growth
84.05%
Trailing 12-Months
Company Description
TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
TGTX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and rapid revenue growth for BRIUMVI, reinforced by encouraging long‑term clinical data and a clear pipeline with multiple near‑term catalysts (ENHANCE, subcutaneous pivotal, early CAR‑T activity). Financially, the company is positioned with positive cash flow expectations, share repurchase activity and reaffirmed 2026 guidance. Notable cautionary items include that reported FY2025 net income was materially boosted by a one‑time tax benefit, near‑term margin/headwind items (inventory reserve and gross‑to‑net seasonality), and elevated near‑term R&D/manufacturing investment for subcutaneous rollout. Overall, the highlights (strong growth, pipeline momentum, capital flexibility) outweigh the lowlights (one‑time accounting benefit, short‑term expense impacts and execution risks), supporting an optimistic outlook.View all TGTX earnings summariesTGTX Stock 12 Month Forecast
Average Price Target
$42.00
▲(50.21% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Nuvalent
―
Ownership Overview
7.27% Insiders
17.45% Mutual Funds
8.46% Other Institutional Investors
42.82% Public Companies and
Individual Investors